Accessibility Menu
Avita Medical Stock Quote

Avita Medical (NASDAQ: RCEL)

$3.75
(0.3%)
+0.01
Price as of November 14, 2025, 4:00 p.m. ET

KEY DATA POINTS

Current Price
$3.75
Daily Change
(0.3%) +$0.01
Day's Range
$3.51 - $3.81
Previous Close
$3.75
Open
$3.60
Beta
1.40
Volume
125,713
Average Volume
584,235
Market Cap
93.2M
Market Cap / Employee
$3.75M
52wk Range
$3.35 - $14.16
Revenue
-
Gross Margin
0.84%
Dividend Yield
N/A
EPS
-$1.81
CAPs Rating
-
Industry
Biotechnology

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

Avita Medical Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
RCEL-70.19%-82.81%-29.66%-85%
S&P+13.19%+87.83%+13.42%+380%

Avita Medical Company Info

AVITA Medical, Inc., through its subsidiaries, engages in the development and commercialization of a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs. Its product, RECELL system, is a device that enables healthcare professionals to produce a suspension of spray-on skin cells using a small sample of the patient's own skin for the treatment of acute thermal burns. The company was founded in December 1992 and is headquartered in Valencia, CA.

News & Analysis

Financial Health

General

Q3 2025YOY Change
Revenue$17.06M-12.7%
Gross Profit$13.88M-15.2%
Gross Margin81.32%-2.4%
Market Cap$126.95M-52.3%
Market Cap / Employee$0.49M0.0%
Employees26025.6%
Net Income-$13.19M18.6%
EBITDA-$8.58M36.4%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q3 2025YOY Change
Net Cash$15.42M-17.3%
Accounts Receivable$9.01M-12.4%
Inventory7.216.2%

Liabilities

Q3 2025YOY Change
Long Term Debt$2.32M-94.9%
Short Term Debt$42.45M0.0%

Ratios

Q3 2025YOY Change
Return On Assets-67.07%3.7%
Return On Invested Capital-65.05%-29.8%

Cash Flow

Q3 2025YOY Change
Free Cash Flow-$6.49M43.3%
Operating Free Cash Flow-$5.53M27.4%

Valuation

MetricQ4 2024Q1 2025Q2 2025Q3 2025YoY Change
Price to Book27.4547.68-30.59-10.55-190.69%
Price to Sales5.212.981.862.00-56.80%
Price to Tangible Book Value28.84-200.30-13.96-7.47-162.77%
Enterprise Value to EBITDA-35.98-20.52-15.89-19.41-6.36%
Return on Equity-231.0%-407.5%-935.7%-1746.3%1045.55%
Total Debt$45.99M$44.07M$44.59M$44.77M-1.87%

No results found

No podcast episodes available.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.